Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 9/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408161 | 0.90 | MCHR1 (0.46) | MCHR1ALDH1A1HPGDSTSHRPOLB | |
| SCHEMBL21316775 | 0.88 | DRD2 (0.45) | MCHR1ALDH1A1HPGDSTSHRCCR3 | |
| SCHEMBL408142 | 0.85 | ALDH1A1 (0.51) | MCHR1ALDH1A1HPGDSTSHRPOLB | |
| SCHEMBL23347872 | 0.83 | ALDH1A1 (0.45) | MCHR1ALDH1A1HPGDSTSHRPOLB | |
| SCHEMBL409337 | 0.82 | MAPK1 (0.48) | MCHR1ALDH1A1HPGDSTSHRLMNA | |
| SCHEMBL23347871 | 0.81 | MCHR1 (0.46) | MCHR1ALDH1A1HPGDSTSHRPOLB | |
| SCHEMBL22000952 | 0.81 | MCHR1 (0.46) | MCHR1ALDH1A1HPGDSTSHRPOLB | |
| SCHEMBL16219434 | 0.80 | ALDH1A1 (0.54) | MCHR1ALDH1A1HPGDSTSHRPOLB | |
| SCHEMBL14655021 | 0.80 | ALDH1A1 (0.49) | MCHR1ALDH1A1HPGDSTSHRPOLB | |
| SCHEMBL19981405 | 0.80 | ALDH1A1 (0.52) | MCHR1ALDH1A1HPGDSTSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | MCHR1 4395/4885ALDH1A1 2803/4885HPGDS 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.